BSD Medical Corporation (BSDM)’s Investor and Analyst Conference Call Transcript

Dan Yankovich – Maxim Group

Got it, and then are those deficits gonna need their own indications is that what you were referring to, when you were referring to special indication.

Clint Carnell – Chief Executive Officer

No, I think from an indication stand point, the team has done, has some nice clinical work under progress and some that we are going to invest into this year with our university affiliations. But we believe there’s some opportunities to expand the safety and back by our clinical research team to give specific indications per specific organ. I think going forward what you’ll find more than likely as I learned about the space more is timing some of the new antenna tips with specific indications so that we can put the marketing efforts behind, having that well-known by the physicians.

There’s also opportunities to improve the perimeters by which we deliver energy, specific to the size of a tumor and vocation of the tumor. It’s kind of our version of big data that I think can be quite compelling as we go out in the market place. So, I still have a lot to learn. I’m just looking at some of the parallels from other business I’ve been in and I think technology is really sound. I think we can turn some of the knowledge, we have in housing the things that can help positions be more predictable say that it provides better outcomes.

Dan Yankovich – Maxim Group

If I could ask just one more. If.. If I understood correctly that the larger focus not razor blade and not the razor. Do you guys see utilization at the head when before this kinda gets adapted more widely?

Clint Carnell – Chief Executive Officer

Ah.. Yes and no. The programs that we’ve set out you know in the end once the vision is out there, the way we measure it and the way sense people need to be in alignment and what we’ll be sharing in the coming weeks and months with investors and analysts is a focus on cases and adoption by customer utilization. And, I think when you look at the building blocks of this business versus others then it is very straight forward than that. And it comes down to can you get more hospitals embracing this, more physicians. And then can you increase the utilization there and it’s quite compelling when you look at the economics. I’m not prepared to go to that part out on a limb. I can just tell you in this case that we have our current sales force focused on one case a week. And once we understand how well we execute on that we’ll be able to give better predictability that what our razor blade model might look like. And we’ll be sharing less likely the one metric that we’ve really focused our own team as well as the outside world on.